EAACI Congress 2025
BackFT07 - Biologicals, biomarkers and microbiome
Friday 13 Jun, 16:45 PM -
18:15 PM Glasgow, United Kingdom
Dochart 2
Flash Talks
16:45
Dupilumab Improves Type 2 Inflammatory Biomarkers Over Time in Patients With Chronic Obstructive Pulmonary Disease
16:52
Reduction in Oral Corticosteroid Burden in Patients With Moderate-to-Severe Asthma Initiating Dupilumab in the Real-World: The RAPID Registry
16:59
A Novel Treatment for Drug-Induced Acute Interstitial Nephritis: Benralizumab
17:06
Omalizumab in CSU: analysis of potential markers of response
17:13
Chronic spontaneous urticaria with wheals, angioedema, or both: Differences in clinical characteristics, biomarkers and treatment response
17:20
Long-term safety of garadacimab in patients with hereditary angioedema from the Phase 3 open-label extension study: an up to 3-year interim analysis
17:27
IL-13 and IL-17A regulate the susceptibility and antiviral response of human rhinovirus in human nasal epithelial cells through Hippo-YAP
17:34
The distinct effects of IL-4, IL-13, and IL-22 in epithelial barrier dysfunction and human skin inflammation
17:41
Dysbiosis promotes the IgE sensitization accompanied with higher PGD2 production in the intestine
17:48
Gut Microbial Bile and Amino Acid Metabolism Associate with Peanut Oral Immunotherapy Failure
17:55
Microbiome variation during Dermatophagoides pteronyssinus cultures used in allergen extracts
18:02
Food emulsifier polysorbate 80 causes gut barrier distruption and inflammation
